Allakos Inc. Stock News

Lirentelimab met histologic co-primary endpoints but missed symptomatic co-primary endpoints in both ENIGMA and KRYPTOS studies Lirentelimab met histologic co-primary endpoints but missed symptomatic co-primary endpoints in both ENIGMA and KRYPTOS studies

Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.

Allakos Inc. (NASDAQ:ALLK) was the target of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,690,000 shares, a decrease of 26.5% from the November 15th total of 2,300,000 shares. Based on an average daily volume of 268,000 shares, the days-to-cover ratio is currently []

Allakos Inc. (NASDAQ:ALLK) traded up 6.3% on Monday after Bank of America raised their price target on the stock from $145.00 to $155.00. Bank of America currently has a buy rating on the stock. Allakos traded as high as $77.53 and last traded at $77.39. 2,470 shares were traded during mid-day trading, a decline of […]

Allakos (NASDAQ:ALLK) had its price objective upped by research analysts at Bank of America from $145.00 to $155.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price objective suggests a potential upside of 100.28% from the stock’s […]

Allakos Inc. (NASDAQ:ALLK) has been given a consensus rating of Buy by the seven brokerages that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued a []

Allakos Inc. (NASDAQ:ALLK) hit a new 52-week low during trading on Friday . The stock traded as low as $74.40 and last traded at $74.40, with a volume of 214 shares traded. The stock had previously closed at $76.39. Several equities research analysts have commented on ALLK shares. Morgan Stanley decreased their target price on [] The post Allakos (NASDAQ:ALLK) Hits New 12-Month Low at $74.40 appeared first on ETF Daily News .

Phase 2 Atopic Dermatitis trial of subcutaneous lirentelimab initiated Phase 2/3 Chronic Spontaneous Urticaria trial of subcutaneous lirentelimab to begin in mid 2022 Phase 2 Asthma trial of subcutaneous lirentelimab to begin in Q4 2022 Additional indications planned in 2023

Equities research analysts forecast that Allakos Inc. (NASDAQ:ALLK) will report earnings of ($1.20) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Allakos earnings, with the lowest EPS estimate coming in at ($1.30) and the highest estimate coming in at ($1.09). Allakos reported earnings per share []

Analysts expect Allakos Inc. (NASDAQ:ALLK) to post earnings of ($1.20) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Allakos earnings, with the highest EPS estimate coming in at ($1.09) and the lowest estimate coming in at ($1.30). Allakos posted earnings of ($0.86) per share during the same quarter last []

Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.

Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.

H.C. Wainwright Stick to Their Buy Rating for Allakos Inc

Shares of Allakos Inc. (NASDAQ:ALLK) have been given an average rating of Buy by the seven ratings firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokerages that []

These drugmakers have big events that should occur before the end of 2021.